Direct-acting Anticoagulants in Chronic Coronary Syndromes.
Chronic coronary syndromes
direct oral anticoagulants
non-valvular AF
percutaneous coronary intervention
secondary prevention
Journal
European cardiology
ISSN: 1758-3764
Titre abrégé: Eur Cardiol
Pays: England
ID NLM: 101574780
Informations de publication
Date de publication:
Feb 2020
Feb 2020
Historique:
received:
16
10
2019
accepted:
23
10
2019
entrez:
18
3
2020
pubmed:
18
3
2020
medline:
18
3
2020
Statut:
epublish
Résumé
Direct-acting oral anticoagulants (DOACs) are easier to use, safer than and as effective as vitamin K antagonists (VKA) in the treatment of non-valvular AF (NVAF). Because of their favourable safety profile and easier use than VKAs, DOACs as anti-thrombotic therapy may have a role in the management of chronic coronary syndromes (CCS). To date, few studies have evaluated DOACs in this setting. Initial studies have focused on patients receiving DOACs for NVAF undergoing acute or elective percutaneous coronary intervention who additionally require dual antiplatelet therapy (DAPT). Rivaroxaban 15 mg once daily plus a P2Y
Identifiants
pubmed: 32180831
doi: 10.15420/ecr.2018.24.2
pmc: PMC7066807
doi:
Types de publication
Journal Article
Review
Langues
eng
Pagination
1-7Informations de copyright
Copyright © 2020, Radcliffe Cardiology.
Déclaration de conflit d'intérêts
Disclosure: ES has received fees for lecture and consulting from AstraZeneca, Bayer, BMS, MSD, Novartis, Roche Diagnostics and Servier. PGS discloses research grants from Bayer, Merck, Sanofi, and Servier and speaking or consulting fees from Amarin, Amgen, AstraZeneca, Bayer/Janssen, Boehringer-Ingelheim, Bristol-Myers-Squibb, Lilly, Merck, Novartis, Novo-Nordisk, Pfizer, Regeneron, Sanofi and Servier.
Références
Cardiovasc Res. 2009 Jun 1;82(3):392-403
pubmed: 19228706
N Engl J Med. 2006 Apr 20;354(16):1706-17
pubmed: 16531616
Clin Cardiol. 2017 Oct;40(10):807-813
pubmed: 28703931
N Engl J Med. 2016 Dec 22;375(25):2423-2434
pubmed: 27959713
Atherosclerosis. 2015 Oct;242(2):639-46
pubmed: 25817329
Eur Heart J. 2012 Nov;33(22):2831-40
pubmed: 22922505
Thromb Haemost. 2013 Sep;110(3):560-8
pubmed: 23846210
Lancet. 2009 May 30;373(9678):1849-60
pubmed: 19482214
N Engl J Med. 2015 May 7;372(19):1791-800
pubmed: 25773268
N Engl J Med. 2017 Oct 5;377(14):1319-1330
pubmed: 28844192
J Thromb Haemost. 2005 Apr;3(4):692-4
pubmed: 15842354
Eur Heart J. 2014 Dec 1;35(45):3155-79
pubmed: 25154388
Eur Heart J. 2018 Mar 1;39(9):750-757a
pubmed: 29186454
N Engl J Med. 2019 Oct 3;381(14):1309-1320
pubmed: 31475798
Drug Des Devel Ther. 2015 Sep 10;9:5203-11
pubmed: 26392754
Int J Cardiol. 2014 Jan 1;170(3):413-8
pubmed: 24321327
N Engl J Med. 2018 Oct 4;379(14):1332-1342
pubmed: 30146935
Lancet. 1996 Nov 16;348(9038):1329-39
pubmed: 8918275
Lancet. 2019 Oct 12;394(10206):1335-1343
pubmed: 31492505
Clin Cardiol. 2016 Oct;39(10):555-564
pubmed: 27565018
Lancet. 2015 Jan 10;385(9963):117-71
pubmed: 25530442
BMJ. 2002 Jan 12;324(7329):71-86
pubmed: 11786451
Lancet. 2019 Sep 28;394(10204):1169-1180
pubmed: 31484629
Can J Cardiol. 2017 Aug;33(8):1027-1035
pubmed: 28754388
Europace. 2014 Mar;16(3):308-19
pubmed: 24351881
Arch Med Sci. 2014 Feb 24;10(1):154-60
pubmed: 24701228
Lancet. 2009 Jul 4;374(9683):29-38
pubmed: 19539361
JAMA. 1999 Dec 1;282(21):2058-67
pubmed: 10591389
Eur Heart J. 2020 Jan 14;41(3):407-477
pubmed: 31504439
Eur Heart J. 2013 Oct;34(38):2949-3003
pubmed: 23996286
Mediators Inflamm. 2011;2011:432080
pubmed: 21772662
PLoS Med. 2006 Nov;3(11):e442
pubmed: 17132052
Lancet. 2018 Jan 20;391(10117):205-218
pubmed: 29132879
N Engl J Med. 2017 Oct 19;377(16):1513-1524
pubmed: 28844193
N Engl J Med. 2014 Dec 4;371(23):2155-66
pubmed: 25399658
Clin Cardiol. 2017 Oct;40(10):797-806
pubmed: 28561986
N Engl J Med. 2002 Sep 26;347(13):969-74
pubmed: 12324552
Circulation. 2012 Dec 18;126(25):e354-471
pubmed: 23166211
Am Heart J. 2015 Apr;169(4):472-8.e5
pubmed: 25819853
N Engl J Med. 2019 Apr 18;380(16):1509-1524
pubmed: 30883055
Arterioscler Thromb Vasc Biol. 2007 Jan;27(1):27-36
pubmed: 17095716